We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Sanofi | NASDAQ:SNY | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.67 | 1.36% | 49.76 | 49.70 | 49.76 | 49.885 | 49.45 | 49.57 | 2,249,372 | 18:08:05 |
From Apr 2019 to Apr 2024
By Michael Dabaie
Regulus Therapeutics Inc. (RGLS) said Tuesday it restructured its collaboration and license agreement with Sanofi (SNY).
Regulus granted Sanofi a world-wide exclusive license to develop and commercialize its investigational drug, targeting miR-21 for all indications including Alport syndrome. Sanofi will assume all future costs and development activities for advancement of RG-012, which is currently in Phase 2 for Alport syndrome.
Regulus is eligible to receive approximately $7 million in upfront and material transfer payments and up to $40 million in development milestone payments. In addition, Sanofi will reimburse Regulus for certain out-of-pocket transition activities and assume Regulus' upstream license royalty obligations.
Shares of Regulus were up 24% at $2.33 premarket.
Alport syndrome is an inherited form of kidney disease. It represents a high unmet medical need with no approved therapy, Regulus said.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
November 06, 2018 08:38 ET (13:38 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
